XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.13

-0.5%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert K. who wrote (16709)	3/7/2004 1:49:35 PM
From: Robert K.	Read Replies (1) of 17367

Well, this means someone will be playing catch up and I bet Raptiva is the one to catch. Either way it is "proof of concept" for Raptiva too. > New Drug to Be Tested on Alopecia Areata We are pleased to announce the NAAF has just been awarded a $200,000 grant to help fund a multi-center clinical trial to determine how the drug Amevive (Alefacept) affects alopecia areata. This grant is from Biogen and will be distributed through the NAAF research grant program to selected investigators willing to design and take part in this trial. Biogen will also supply the drugs necessary for the trial directly to the investigators; these drugs are valued at over a million dollars. This is a "proof of concept" study to help us determine if and how alopecia areata is mediated by T-Cells.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next